CN103566068A - Compound composition with retina protection function and application thereof - Google Patents
Compound composition with retina protection function and application thereof Download PDFInfo
- Publication number
- CN103566068A CN103566068A CN201210381431.8A CN201210381431A CN103566068A CN 103566068 A CN103566068 A CN 103566068A CN 201210381431 A CN201210381431 A CN 201210381431A CN 103566068 A CN103566068 A CN 103566068A
- Authority
- CN
- China
- Prior art keywords
- compound recipe
- retina
- vitamin
- tool
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 37
- 210000001525 retina Anatomy 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title abstract description 15
- 230000006870 function Effects 0.000 claims abstract description 35
- 239000000284 extract Substances 0.000 claims abstract description 20
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 10
- 235000012680 lutein Nutrition 0.000 claims abstract description 7
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 7
- 229960005375 lutein Drugs 0.000 claims abstract description 7
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 7
- 239000001656 lutein Substances 0.000 claims abstract description 7
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 7
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 6
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229930003571 Vitamin B5 Natural products 0.000 claims abstract description 6
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims abstract description 6
- 229960002079 calcium pantothenate Drugs 0.000 claims abstract description 6
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000009492 vitamin B5 Nutrition 0.000 claims abstract description 6
- 239000011675 vitamin B5 Substances 0.000 claims abstract description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 6
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 6
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000001466 Ribes nigrum Nutrition 0.000 claims abstract description 5
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 5
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 5
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940055416 blueberry extract Drugs 0.000 claims abstract description 5
- 235000019216 blueberry extract Nutrition 0.000 claims abstract description 5
- 239000002552 dosage form Substances 0.000 claims abstract description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 5
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 5
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 5
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 5
- 239000011718 vitamin C Substances 0.000 claims abstract description 5
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 5
- 239000011709 vitamin E Substances 0.000 claims abstract description 5
- 229940046009 vitamin E Drugs 0.000 claims abstract description 5
- 239000011701 zinc Substances 0.000 claims abstract description 5
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims abstract description 4
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract 2
- 239000000470 constituent Substances 0.000 claims description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 241000628997 Flos Species 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- -1 hydroxypropyl Chemical group 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 206010025421 Macule Diseases 0.000 claims description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000003002 pH adjusting agent Substances 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 241001312569 Ribes nigrum Species 0.000 claims description 4
- 244000078534 Vaccinium myrtillus Species 0.000 claims description 4
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 4
- 229930003270 Vitamin B Natural products 0.000 claims description 4
- 235000009392 Vitis Nutrition 0.000 claims description 4
- 241000219095 Vitis Species 0.000 claims description 4
- 229930014669 anthocyanidin Natural products 0.000 claims description 4
- 150000001452 anthocyanidin derivatives Chemical class 0.000 claims description 4
- 235000008758 anthocyanidins Nutrition 0.000 claims description 4
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 235000019156 vitamin B Nutrition 0.000 claims description 4
- 239000011720 vitamin B Substances 0.000 claims description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 239000008351 acetate buffer Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 229910021538 borax Inorganic materials 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 229950002366 nafoxidine Drugs 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 18
- 238000010521 absorption reaction Methods 0.000 abstract description 8
- 239000003889 eye drop Substances 0.000 abstract description 6
- 244000194101 Ginkgo biloba Species 0.000 abstract 2
- 241000201295 Euphrasia Species 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 240000001890 Ribes hudsonianum Species 0.000 abstract 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 abstract 1
- 229940002386 calendula officinalis extract Drugs 0.000 abstract 1
- 229940119217 chamomile extract Drugs 0.000 abstract 1
- 235000020221 chamomile extract Nutrition 0.000 abstract 1
- IKALZAKZWHFNIC-JIZZDEOASA-L dipotassium;(2s)-2-aminobutanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O IKALZAKZWHFNIC-JIZZDEOASA-L 0.000 abstract 1
- 229940087603 grape seed extract Drugs 0.000 abstract 1
- 235000002532 grape seed extract Nutrition 0.000 abstract 1
- 230000035807 sensation Effects 0.000 abstract 1
- 239000001717 vitis vinifera seed extract Substances 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 43
- 230000035945 sensitivity Effects 0.000 description 31
- 239000006196 drop Substances 0.000 description 20
- 238000000034 method Methods 0.000 description 15
- 230000004483 macular pigment optical density Effects 0.000 description 10
- 230000002123 temporal effect Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 210000004087 cornea Anatomy 0.000 description 6
- 230000004438 eyesight Effects 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 210000000695 crystalline len Anatomy 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000002189 macula lutea Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000005266 casting Methods 0.000 description 3
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 3
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 238000005375 photometry Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 230000004243 retinal function Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010058646 Arcus lipoides Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- 208000002367 Retinal Perforations Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038897 Retinal tear Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 201000000351 arcus senilis Diseases 0.000 description 1
- 238000012865 aseptic processing Methods 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940088747 lutein 15 mg Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 208000038015 macular disease Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000004083 nasolacrimal duct Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 229940078333 vitamin b 12 6 mg Drugs 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Images
Abstract
The invention discloses a compound composition with retina protection function and application thereof, and the composition comprises the following components: 1.00-3.00wt% of water-soluble lutein, 0.80-1.20wt% of potassium L-aspartate, 0.1-0.2 wt% of hyaluronic acid, 0.08-0.12wt% of vitamin B5, 0.08-0.12wt% of vitamin B6, 0.04-0.07wt% of vitamin B12, 0.04-0.07wt% of vitamin C, 0.04-0.07wt% of vitamin E, 0.03-0.06wt% of chamomile extract, 0.03-0.06wt% of blackcurrant extract, 0.003-0.006wt% of Morus alba blueberry extract, 0.003-0.006wt% of eyebright herb powder, 0.003-0.006wt% of zinc, 0.003-0.006wt% of calendula officinalis extract, 0.003-0.006wt% of gingko extract, 0.03-0.06wt% of gingko seed extract, 0.05-0.06 wt% of grape seed extract. The compound composition can be prepared into various dosage form products, particularly can be prepared into eye-care solution or eye drop with the best effect, does not cause foreign body sensation when being used by a user, and has the efficacy of quick absorption, eye moistening effect and effective fatigue resistance.
Description
Technical field
The present invention about a kind of with compound recipe constituent and application, particularly about a kind of compound recipe constituent and application of tool retina defencive function.
Background technology
Significantly change along with modern's job specification, working environment and recreation kenel, the long-time eyes that use become normality unavoidablely, Just because of this, the maintenance of modern's eyes and ocular disease generation and aging prevention have also become one of more and more valued problem.Particularly, eyes are often because there is associated change in the gradual age, comprise normal visual deterioration and morbid state variation etc., often can seriously affect the function of eyes, these variations comprise: cataractous development, sclerosis, opacification, compliance (pliability) lower and crystalline lens yellow; Cornea yellow and opacification; Presbyopia; Girder stops up, and causes intraocular pressure to be accumulated and glaucoma; The unsteady thing increasing in camera oculi posterior water; Iris is opened and is ossify on a large scale and reduce; The speckle shape rotten (age-related macular degeneration, AMD) that age is relevant; In arteria retina, there is the formation of atherosclerotic deposition; Xerophthalmia syndrome; And the attenuating of the sensitivity of rod and the cone and the horizontal adaptive capacity of light.Relevant visual degradation of age comprises the impairment of visual sensitivity, visual contrast, color and degree of depth susceptibility, crystalline lens adjusting, lightsensitivity and darkness adaption etc.Age, relevant variation also comprised the change of iris color outward appearance, and the formation of arcus senilis.More than change each different component part that may occur in eyes, comprise that cornea, sclera, girder, iris, crystalline lens, camera oculi posterior water and retina all may be subject to aging and excessively use eyesight to affect.
Phylloxanthin is the most important nutrition of human retina, and the phylloxanthin in human body can also filter the light of ninety percent above blue light wavelength, avoids the injury of this high light, and blue light is the generation of accelerating oxidation effect likely.Phylloxanthin provides the nutrition of eye and skin to support, at the macula area (center of vision) of eye retina, and the crystalline lens phylloxanthin that contains a large amount.Phylloxanthin is the important composition of macula retinae portion, is used for preventing senile macular diseases quite effective in cure in recent years in American-European medical circle, and the retinopathy causing as myopia for other also thinks effective.
Macula lutea is positioned at optical fundus retinal centre, in the retinal tissue layer of macula lutea body, has a large amount of phylloxanthins, and early stage anatomist claims this region for " macula lutea " or " yellow point ", and this is dense due to phylloxanthin, and color presents yellow.Macula lutea is the place that photoreceptor cell，photosensory cell is assembled, and is responsible for providing color and detail in visual field central authorities.Research for macular area pigment (macular pigment, MP) has in recent years become a large focus.And how for the Research foundation of this technical field, develop a kind of collyrium that can absorb fast, effectively protect retinal function, for modern, relieve eye fatigue, avoid eyesight excessively to use causing eye pathological changes, more become the urgently target of development.
Summary of the invention
Edge this, object of the present invention is to provide a kind of compound recipe constituent that can absorb fast, effectively protect retinal function.
The technological means that the problem that the present invention is solution known techniques adopts is a kind of compound recipe constituent of tool retina defencive function, its component comprises: the water-soluble lutein of 1.00-3.00wt%, the L-acid, aspartic potassium of 0.80-1.20wt%, the hyaluronic acid of 0.1%-0.2wt%, the vitamin B of 0.04-0.12wt%, the vitamin C of 0.04-0.07wt%, the vitamin E of 0.04-0.07wt%, the Flos Matricariae chamomillae extract of 0.03-0.06wt%, the Ribes nigrum L. extract of 0.03-0.06wt%, the bilberry blue berry extract of 0.003-0.006wt%, the Herba Euphrasiae Regelii powder of 0.003-0.006wt%, the zinc of 0.003-0.006wt%, the Flos Inulae extract of 0.003-0.006wt%, the biloba extract thing of 0.003-0.006wt%, the Fructus Lycii of 0.03-0.06wt%, the anthocyanidin of 0.03-0.06wt%, the Semen Vitis viniferae of 0.05-0.07wt%.
The vitamin B composition of the compound recipe constituent of above-mentioned tool retina defencive function, can comprise vitamin B5, vitamin B6 and vitamin B12; Be preferably the vitamin B5 of 0.08-0.12wt%, the vitamin B12 of the vitamin B6 of 0.08-0.12wt%, 0.04-0.07wt%.
The pH value of the compound recipe constituent of above-mentioned tool retina defencive function can preferably be adjusted between 3.5 to 5.8 by pH adjusting agent, and wherein this pH adjusting agent comprises phosphate, borate, acetate buffer and citrate.
The viscosity of the compound recipe constituent of above-mentioned tool retina defencive function can preferably be adjusted between 10 to 25000mpas by viscosity promoting agent, and wherein this viscosity promoting agent comprises hydroxypropyl emthylcellulose, sanlose, methylcellulose, polyvinyl nafoxidine ketone, polyvinyl alcohol, glucosan and polyacrylic acid.
The compound recipe of above-mentioned tool retina defencive function forms system can be by tension regulator to regulate its tension value, and wherein this tension regulator comprises: sodium chloride, potassium chloride, glycerol, mannitol, Sorbitol, sodium borate and sodium acetate.
The compound recipe constituent of above-mentioned tool retina defencive function during with collyrium pattern, comprises with solvent and is supplemented to 100wt%, and this solvent is preferably water or organic solvent, and can further comprise pharmaceutically acceptable adjuvant.In addition, and can add the Benzalkonii Chloridum of 0.01wt%.
Via the technology used in the present invention means, by the tired formula of releiving of its uniqueness, collocation micromolecule effect property composition can directly penetrate into cornea and be absorbed by the body, and breaks through absorption of human body barrier, promotes bioavailability.Break through multiple effect composition and directly click and enter the absorbance problem of eyes, and unique micromolecule effect property composition, can directly penetrate into cornea and be absorbed by the body to reach high-absorbility.In addition, the collocation uniqueness tired formula of releiving, can effectively alleviate the fatigue of eye, really reaches prevention and health care effect, and constituent of the present invention is all solubleness and dissolves completely, foreign sense during use, wherein contained water-soluble lutein, also can effectively prevent macula retinae portion pathological changes, and contained hyaluronic acid can reach moistening effect, fully moisten eyes, the fatigue of releiving, effectively relieves the dry and astringent discomfort of eyes.
The compound recipe constituent of tool retina defencive function of the present invention; for example, divided by solution pattern outer (collyrium); and can be processed into through conventional process in the technology of the present invention field; with ingot technology processed, make the lozenge dosage forms such as double-deck ingot, effervescent tablet, slow release ingot; or be directly filled into and in capsule shells, make capsule formulation; also can be made into health nutrient and supplement beverage pattern, the applicable various market demands of this compound recipe constituent, and be designed to various dosage forms.Above-mentioned multiple dosage form, can be widely used in the fields such as health food and pharmaceuticals, promotes the surcharge of Related product.
Accompanying drawing explanation
Fig. 1 shows that eye compares trendgram by the macular pigment optical density value (MPOD) of drop group (Eyedrop Group) and oral group (Oral Group);
Fig. 2 shows that eye compares trendgram with the spatial contrast sensitivity (SCS) of drop group (Eyedrop Group) and oral group (Oral Group);
Fig. 3 shows that eye compares trendgram with the temporal contrast sensitivity (TCS) of drop group (Eyedrop Group) and oral group (Oral Group).
The specific embodiment
The present invention discloses a kind of compound recipe constituent of tool retina defencive function, and its component mainly comprises: water-soluble lutein, L-acid, aspartic potassium, hyaluronic acid, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin E, Flos Matricariae chamomillae extract, Ribes nigrum L. extract, bilberry blue berry extract, Herba Euphrasiae Regelii powder, zinc, Flos Inulae extract, biloba extract thing, Fructus Lycii, anthocyanidin, Semen Vitis viniferae; And optionally add Benzalkonii Chloridum, the explanation of its proportion of composing scope as after.
Embodiment 1: resisting fatigue collyrium
The compound recipe constituent of tool retina defencive function of the present invention arranges as shown in table 1 with each component and the proportion of composing of collyrium pattern.
Table 1
| Composition | Formula (weight) | Ratio (wt%) |
| Water-soluble lutein | 15mg | 1.00-3.00wt% |
| L-acid, aspartic potassium | 12mg | 0.80-1.20wt% |
| Vitamin B5 | 1.2mg | 0.08-0.12wt% |
| Hyaluronic acid | 1.5mg | 0.1%-0.2%wt% |
| Vitamin B6 | 6mg | 0.04-0.07wt% |
| Vitamin B12 | 6mg | 0.04-0.07wt% |
| Vitamin C | 6mg | 0.04-0.07wt% |
| Vitamin E | 6mg | 0.04-0.07wt% |
| Flos Matricariae chamomillae extract | 4mg | 0.03-0.06wt% |
| Ribes nigrum L. extract | 6mg | 0.03-0.06wt% |
| Bilberry blue berry extract | 0.5mg | 0.003-0.006wt% |
| Benzalkonii Chloridum | 0.5mg | 0.003-0.006wt% |
| Herba Euphrasiae Regelii powder | 0.5mg | 0.003-0.006wt% |
| Zinc | 0.5mg | 0.003-0.006wt% |
| Flos Inulae extract | 0.5mg | 0.003-0.006wt% |
| Biloba extract thing | 0.05mg | 0.003-0.006wt% |
| Fructus Lycii | 0.5mg | 0.03-0.06wt% |
| Anthocyanidin | 0.5mg | 0.03-0.06wt% |
| Semen Vitis viniferae | 6mg | 0.05-0.07wt% |
| Water | Be supplemented to 100wt% | Be supplemented to 100wt% |
The formulation weight that table 1 provides is only a preferred embodiment, and its actual allotment still can appropriately adjust according to proportion shown in table, and the collyrium made from aforementioned proportion, and also visual demand is added other suitable pharmaceutically acceptable adjuvants in addition.Every extract in table 1 is purchased from Taiwan Tong Yuan enterprise, the industrial ,Ji Luodun of luxuriant generation trading company.For example, and the solvent that above-mentioned collyrium is used is generally water solublity solvent (water), also can use other pharmaceutically acceptable organic solvents, as known person in prior art etc.
In the preparation, conventionally need regulate pH value, tension force and the viscosity etc. of collyrium simultaneously.Wherein, in order to regulate suitable pH value, can use habitual pH adjusting agent, for example acid or alkali, or suitable buffer agent, as phosphate buffer, borate buffer, acetate buffer, or citrate buffer agent etc.In order to regulate the tension force (tonicity) of product, can example be usually used in the tension regulator of this object, for example, sodium chloride, potassium chloride, glycerol, mannitol, Sorbitol, sodium borate, sodium acetate or other etc.Viscosity system gives adjustment person via using its amount can obtain the suitable viscosity promoting agent of wanted viscosity level in prescription, typical example comprises cellulose derivative, for example, hydroxypropyl emthylcellulose (hydroxypropyl methylcellulose, HPMC), sanlose, methylcellulose, polyvinyl nafoxidine ketone, polyvinyl alcohol, glucosan (dextrans), polyacrylic acid etc.The addition of these polymer, except being decided by required viscosity level, is also decided by polymer used, is the easily decision maker of this skill person that is familiar with.Except improving viscosity, the use of these polymer also has other benefits, for example lubricant effect to eyes, and the stabilization effect to tear film, and these are all of value to for the patient who suffers from such as dryness eyes etc.
If need to use antimicrobial, for example this prepared product is being packaged in multi-agent container, is needing, in non-situation about being packaged within single dose container, can use oneself to know the medicament that can be used for this object, for example quaternary ammonium compound is as Lv Benzyl alkane ammonium (benzalkonium chlride), benzyl alcohol, mercury salt, thimerosal (thimersal), chlorine six pyridines (chiorohexidine), methaform (chlorobutanol) or other etc., separately person or the person of being used in combination.
It is prepared that resisting fatigue collyrium whole process of the present invention is all aseptic processing procedure, comprise all operations in the environment of dust-free sterile of filling whole process of medicinal liquid, its step comprises: blow ring, bottle blowing, filling, seal and move back the steps such as bottle, particularly, bottle blowing wherein, filling, sealing step are for once completing.In addition, liquid medicine bottle and medicinal liquid, before sealing, can directly not contact with operator, and filling machine has the function of automatic cleaning (CIP) and autosterilization (SIP), therefore can keep good production quality.
The typical amounts of resisting fatigue collyrium of the present invention is for being formulated as 15ml, and pH value is preferably adjustable between 3.5 to 5.8, and viscosity is preferably adjustable between 10 to 25000mpas.
In above-mentioned resisting fatigue collyrium, its micromolecule effect property composition can be broken through the barrier of ocular absorption via following three kinds of absorption approach, is effectively absorbed by the body.
Absorption approach I:
Collyrium splashes into after eye, and its micromolecule effect property composition is directly absorbed by circumference of eyes blood vessel.
Absorption approach II:
Micromolecule effect property composition penetrates into cornea, through front aqueous humor, via aqueous humor circulation, by drainage point row's water inlet crystal, enters vitreous body, via peripheral retinal tear blood vessel, absorbs.
Absorption approach III:
The high intestinal absorption rate of uniqueness and the bioavailability that by collyrium component, have, enter nasal cavity by nasolacrimal duct, by esophagus, enters Gastrointestinal Wall Absorption.
Embodiment 2: resisting fatigue collyrium is used the impact of drop and oral supplement on the positive influences of eye macular pigment and other functions and eye
In order to confirm that the resisting fatigue collyrium of previous embodiment 1 is for positive influences and the effect of eye function, carry out in the present embodiment the clinical effectiveness comparison of drop and oral supplement for eye.Its experimental technique is as follows:
Adopt heterochromatic flicker photometer (Heterochromatic flicker photometry, HFP) 43 experimenters' right eye being carried out to macular pigment optical density MPOD (Macular Pigment Optimal Density) measures, measure dazzle toleration, temporal contrast sensitivity, spatial contrast sensitivity, monitor vision, intraocular pressure simultaneously.
Test group is divided into two groups: (1) oral supplement group: 22 experimenters, cast phylloxanthin oral supplement, and give the phylloxanthin of 30mg every day.(2) eye drop group: 21 experimenters, used the collyrium containing 15mg/10ml water-soluble lutein every day, one day twice, for eye function, measures, to confirm the effect of drop for the eye of containing water-soluble phylloxanthin, and compare with oral phylloxanthin.For experimenter, carry out following test: macula retinae portion density (Macular Pigment Optimal Density, MPOD) test, spatial contrast sensitivity (Spatial contrast sensitivity, SCS), temporal contrast sensitivity (Time contrast sensitivity, TCS).
1. object and method
1.1 experimenters include condition in
The experimenter in 50-65 year, totally 43 (every experimenter checks right eye, totally 43).
I. the age is 50 ~ 65 years old, male or female.
II. get rid of inside and outside ophthalmic and family's history of disease.
III. colour vision is normal.Without epilepsy history.Non-smoking history.
The approval of human trial committee of Taibei Rongmin General Hospital has been passed through in this experiment.
1.2 experimental technique
1.2.1 the measurement of macular pigment optical density
Macular pigment optical density is used heterochromatic flicker photometry (Heterochromatic flicker photometry, HFP) to measure.
In this experiment, the detecting instrument of macular pigment optical density and method are at (Ophthalmology and Physiological Optics such as Tang in 2004, the 06th phase in 2004) on experiment basis, only changed paracentral fixation point position in passage of scintillation light frequency and HFP, in this experiment, detecting light blue light flicker frequency is 14Hz, with reference to light green glow flicker frequency, be 10Hz, select the conduct of 7 °, other center to detect reference point.
1.2.2 the measurement of spatial contrast sensitivity
Use VSG series software (Cambridge Research System, HK) measurement space contrast sensitivity function.Inspection is apart from 2.5m, and stimulating sighting target is the disk of 1.4 ° of diameters, is Sine Modulated separatrix grid on it.Measure the contrast sensitivity under 6.0,12.0,24.0c/d spatial frequency.Bar grid vision (grating acuity) is used square wave bar grid to detect, sensitivity when Record Comparison degree is maximum.The brightness of bar grid is measured by spectrophotometer (Topcon SR-3).Before checking, use trial lens to correct tested object ametropia.Inspection is carried out in darkroom, checks apart from 2.5m, and the detection of each spatial frequency is by random sequence appearance, and whole checking process approximately needs 7min.
1.2.3 the measurement of temporal contrast sensitivity
Temporal contrast sensitivity function is also to use VSG series software to measure.Inspection is apart from 2.5m, and stimulating sighting target is 1 ° of big or small green spot, and hot spot brightness is Sine Modulated variation ，Qi center has an intersection to watch sighting target attentively.Measure the contrast sensitivity under 6.0,12.0,24.0,32.0Hz.Flicker fusion frequency (CriticalFlicker Frequency, CFF) is measured at contrast peak.Inspection is carried out in darkroom, checks apart from 2.5m, and the detection of each temporal frequency is by random sequence appearance, and whole inspection approximately needs 10min.
1.2.4 statistical method
The one factor analysis of variance that relatively adopts SPSS 13.0 to add up in package softwares of space, temporal contrast sensitivity function, the relatively employing t method of inspection of bar grid vision, flicker fusion frequency.
2 results
2.1 macular pigment optical density values (Macular pigment optical density, MPOD)
Experimental result is as shown in table 2 and the 1st figure.Experimenter is divided into two groups at random, and drop group and oral group for eye are respectively 0.34 ± 0.0456,0.35 ± 0.0362 at experiment initial (Day 0) eye by drop group and oral group of experimenter's macular pigment optical density meansigma methods.
Casting phylloxanthin after 84 days, eye increases to respectively by the macular pigment optical density meansigma methods of drop group and oral group: 0.46 ± 0.04,0.39 ± 0.03.
Table 2: eye by the macular pigment optical density value (MPOD) of drop group and oral group relatively
Table 2
2.2 spatial contrast sensitivities (Spatial contrast sensitivity, SCS)
Experimental result is as shown in table 3 and the 2nd figure.Experimenter is divided into two groups at random, and drop group and oral group for eye are respectively 33.41 ± 0.0446c/d, 33.42 ± 0.0395c/d at experiment initial (Day 0) eye by drop group and oral group of experimenter's spatial degrees contrast sensitivity meansigma methods.
Table 3: eye with the spatial contrast sensitivity (SCS) of drop group and oral group relatively
Table 3
Casting phylloxanthin after 84 days, eye increases to by the spatial degrees contrast sensitivity meansigma methods of drop group and oral group: 38.21 ± 0.03c/d, 34.65 ± 0.04c/d.
2.3 temporal contrast sensitivitys (Time contrast sensitivity, TCS)
Experimental result is as shown in table 4 and the 3rd figure.Experimenter is divided into two groups at random, and drop group and oral group for eye are respectively 37.96 ± 0.03c/d, 37.41 ± 0.04c/d at experiment initial (Day 0) eye by drop group and oral group of experimenter's time degree contrast sensitivity meansigma methods.
Casting phylloxanthin after 84 days, eye increases to by the time degree contrast sensitivity meansigma methods of drop group and oral group: 42.43 ± 0.04c/d, 38.28 ± 0.04c/d.
Table 4: eye with the temporal contrast sensitivity (Time contrast sensitivity, TCS) of drop group and oral group relatively
Table 4
By above-mentioned the results show, through eye, with drop, supplement and oral supplementation cast experimenter after 84 days, macula area spatial density (MPOD) between its two groups, spatial contrast sensitivity (SCS), temporal contrast sensitivity (TCS) all have and are showing difference.Above-mentioned result of study shows, uses the eye drop group of containing water-soluble phylloxanthin, and the clinical visual performance index that represents meaning of its every tool is all higher than oral group of general phylloxanthin, with a definite effect with drop of this clinical research confirmation containing water-soluble phylloxanthin.
In addition; compound recipe constituent by tool retina defencive function of the present invention is imitated property composition with unique micromolecule of collyrium pattern; can directly penetrate into cornea and be absorbed by the body to reach high-absorbility, the uniqueness of simultaneously arranging in pairs or groups releive fatigue and moisturizing formula, can effectively alleviate the fatigue of eye; really reach prevention and health care effect; and can fully moisten eyes, the fatigue of releiving, effectively relieves the dry and astringent discomfort of eyes; separately add water-soluble lutein, there is the effect of prevention macula retinae portion pathological changes.
As seen from the above embodiment; value in the true tool industry of compound recipe constituent of tool retina defencive function provided by the present invention; only above narration is only preferred embodiment explanation of the present invention; allly be skillful in this skill person when can do according to above-mentioned explanation other all improvement, only these changes still belong in spirit of the present invention and following defined the scope of the claims.
Claims (12)
1. the compound recipe constituent of a tool retina defencive function, its component comprises: the water-soluble lutein of 1.00-3.00wt%, the L-acid, aspartic potassium of 0.80-1.20wt%, the hyaluronic acid of 0.1%-0.2wt%, the vitamin B of 0.04-0.12wt%, the vitamin C of 0.04-0.07wt%, the vitamin E of 0.04-0.07wt%, the Flos Matricariae chamomillae extract of 0.03-0.06wt%, the Ribes nigrum L. extract of 0.03-0.06wt%, the bilberry blue berry extract of 0.003-0.006wt%, the Herba Euphrasiae Regelii powder of 0.003-0.006wt%, the zinc of 0.003-0.006wt%, the Flos Inulae extract of 0.003-0.006wt%, the biloba extract thing of 0.003-0.006wt%, the Fructus Lycii of 0.03-0.06wt%, the anthocyanidin of 0.03-0.06wt%, the Semen Vitis viniferae of 0.05-0.07wt%.
2. the compound recipe constituent of tool retina defencive function as claimed in claim 1, the group that wherein this vitamin B selects the vitamin B5 of free 0.08-0.12wt%, the vitamin B12 of the vitamin B6 of 0.08-0.12wt%, 0.04-0.07wt% and arbitrary combination thereof form.
3. the compound recipe constituent of tool retina defencive function as claimed in claim 1, this compound recipe constituent further comprises the Benzalkonii Chloridum of 0.01wt%.
4. have as claimed in claim 1 a compound recipe constituent of retina defencive function, wherein the pH value of this compound recipe constituent is to adjust between 3.5 to 5.8 by pH adjusting agent.
5. the compound recipe constituent of tool retina defencive function as claimed in claim 4, wherein this pH adjusting agent comprises phosphate, borate, acetate buffer and citrate.
6. the compound recipe constituent of tool retina defencive function as claimed in claim 1, wherein the viscosity of this compound recipe constituent is to adjust between 10 to 25000mpas by viscosity promoting agent.
7. the compound recipe constituent of tool retina defencive function as claimed in claim 6, wherein this viscosity promoting agent comprises hydroxypropyl emthylcellulose, sanlose, methylcellulose, polyvinyl nafoxidine ketone, polyvinyl alcohol, glucosan and polyacrylic acid.
8. the compound recipe constituent of tool retina defencive function as claimed in claim 1; wherein this compound recipe constituent be by tension regulator to regulate its tension value, this tension regulator comprises: sodium chloride, potassium chloride, glycerol, mannitol, Sorbitol, sodium borate and sodium acetate.
9. the compound recipe constituent of tool retina defencive function as claimed in claim 1, can further comprise solvent and be supplemented to 100wt%, and this solvent is water or organic solvent.
10. the compound recipe constituent of tool retina defencive function as claimed in claim 1, wherein this compound recipe constituent further comprises pharmaceutically acceptable adjuvant.
The compound recipe constituent of 11. tool retina defencive functions as claimed in claim 1, wherein the dosage form of this compound recipe constituent is solution, lozenge or capsule.
The compound recipe constituent of 12. tool retina defencive functions as claimed in claim 1, wherein this retina defencive function is for preventing macula retinae portion to degenerate or slowing down excess eye-using fatigue.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW101128811 | 2012-08-09 | ||
| TW101128811A TW201406382A (en) | 2012-08-09 | 2012-08-09 | Compound composition having retina protection function and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103566068A true CN103566068A (en) | 2014-02-12 |
| CN103566068B CN103566068B (en) | 2016-10-12 |
Family
ID=50039349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210381431.8A Expired - Fee Related CN103566068B (en) | 2012-08-09 | 2012-10-10 | Compound composition with retina protection function and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN103566068B (en) |
| TW (1) | TW201406382A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109549985A (en) * | 2018-12-17 | 2019-04-02 | 广州市中科慢性病医学研究院 | A kind of absorbing transmission from skin quickly repairs the small-molecular peptides eye refreshing drop of eyesight |
| CN110882314A (en) * | 2019-11-26 | 2020-03-17 | 李智康 | Eye lotion and preparation method thereof |
| CN110945115A (en) * | 2017-07-20 | 2020-03-31 | 国立研究开发法人理化学研究所 | Method for preserving nerve tissue |
| WO2020201058A1 (en) * | 2019-03-29 | 2020-10-08 | Evonik Operations Gmbh | Treatment and prevention of infections by herpesviridae with delphinidin-3-glucoside |
| CN115461048A (en) * | 2020-03-11 | 2022-12-09 | 博士伦爱尔兰有限公司 | Compositions and methods for ocular health comprising AREDS and vitamin B complexes |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2660366C1 (en) * | 2017-03-31 | 2018-07-05 | Общество с ограниченной ответственностью "ПРОФИТ ФАРМ" | Agent for prevention and treatment of ocular diseases, such as retinal diseases, glaucoma and cataract |
| AU2021233236A1 (en) * | 2020-03-11 | 2022-09-15 | Bausch + Lomb Ireland Limited | Compositions and methods for age related eye diseases comprising high concentrations of vitamins |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102686274A (en) * | 2009-10-23 | 2012-09-19 | （株）宇宙力量 | Face support having a drug carrier |
-
2012
- 2012-08-09 TW TW101128811A patent/TW201406382A/en unknown
- 2012-10-10 CN CN201210381431.8A patent/CN103566068B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102686274A (en) * | 2009-10-23 | 2012-09-19 | （株）宇宙力量 | Face support having a drug carrier |
Non-Patent Citations (2)
| Title |
|---|
| 张日新等: "中药对青光眼视功能保护作用研究进展", 《实用中医药杂志》, no. 02, 15 February 2009 (2009-02-15), pages 132 - 133 * |
| 王文美等: "护网明目散治疗玻璃体积血对视网膜保护作用的形态观察", 《国际眼科杂志》, no. 02, 28 February 2010 (2010-02-28), pages 254 - 255 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110945115A (en) * | 2017-07-20 | 2020-03-31 | 国立研究开发法人理化学研究所 | Method for preserving nerve tissue |
| CN109549985A (en) * | 2018-12-17 | 2019-04-02 | 广州市中科慢性病医学研究院 | A kind of absorbing transmission from skin quickly repairs the small-molecular peptides eye refreshing drop of eyesight |
| WO2020201058A1 (en) * | 2019-03-29 | 2020-10-08 | Evonik Operations Gmbh | Treatment and prevention of infections by herpesviridae with delphinidin-3-glucoside |
| WO2020201050A1 (en) * | 2019-03-29 | 2020-10-08 | Evonik Operations Gmbh | Preparations containing berry extracts for use in the prophylaxis and/or treatment of viral infections caused by herpesviridae |
| CN110882314A (en) * | 2019-11-26 | 2020-03-17 | 李智康 | Eye lotion and preparation method thereof |
| CN110882314B (en) * | 2019-11-26 | 2021-11-02 | 李智康 | Eye lotion and preparation method thereof |
| CN115461048A (en) * | 2020-03-11 | 2022-12-09 | 博士伦爱尔兰有限公司 | Compositions and methods for ocular health comprising AREDS and vitamin B complexes |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201406382A (en) | 2014-02-16 |
| CN103566068B (en) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103566068B (en) | Compound composition with retina protection function and application thereof | |
| CN103576337B (en) | Combine the eyeglass of myopia control optical element and poisonous fungus alkaline agent | |
| CN109803652A (en) | Ophthalmic pharmaceutical compositions and its associated uses | |
| Oshika | Ocular adverse effects of neuropsychiatric agents: incidence and management | |
| Charles et al. | Comparison of 2 femtosecond lasers for flap creation in myopic laser in situ keratomileusis: one-year results | |
| WO2021021646A1 (en) | Compositions and methods for treatment of presbyopia | |
| US9226940B2 (en) | Method of treating ocular disorders | |
| Filippello et al. | Reply: Efficacy and safety of transepithelial corneal collagen crosslinking | |
| Zhu et al. | Daily or less frequent topical 1% atropine slows defocus-induced myopia progression in contact lens-wearing guinea pigs | |
| US8178134B2 (en) | Synergistic herbal ophthalmic formulation for lowering intraocular pressure in case of glaucoma | |
| CN105983004A (en) | Composition capable of alleviating asthenopia and preparation method | |
| CA3217324A1 (en) | Method and pharmaceutical composition for treating myopia | |
| CN1985801A (en) | Benzydalysine eye drop and its preparing method | |
| CN102988278A (en) | Bromfenac sodium hydrate eye drops and preparation method thereof | |
| Ahn et al. | Changes in spherical aberration after various corneal surface ablation techniques | |
| Panthagani et al. | Cystoid macular edema following intravitreal chemotherapy treatment for retinoblastoma | |
| CN105726697B (en) | Anti-asthenopia rose composition, eye drop and preparation method of eye drop | |
| Örnek et al. | Short-term effect of topical brinzolamide on human central corneal thickness | |
| MX2010013439A (en) | Compounds useful for the prevention or treatment of accomodative asthenopia. | |
| Duarte et al. | Acute angle-closure glaucoma caused by topiramate–a drug complication that can lead to blindness | |
| Vuković et al. | Urrets-Zavalia syndrome following posterior segment surgery: Case report and review of literature | |
| KR20220108762A (en) | Compositions of dietary supplements and/or nutritional additives for food use, single dosage forms thereof, and such improvements in persons in need of improved visual performance including contrast sensitivity in nature, including those suffering from at least one eye disease, particularly rhinorrhea. their use for | |
| Revar et al. | An Overview On Glaucoma: Silent Thief Of Sight | |
| CN103655566B (en) | Compound purposes in the medicine of preparation preventing and treating glaucoma | |
| CN105983005A (en) | Composition capable of alleviating asthenopia and preparation method of composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161012 Termination date: 20171010 |